PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
Lin Zhou, Hongyu Zhang, Shuyi Wang, Hong Zhao, Yongnan Li, Juqian Han, Hongxu Zhang, Xiaoyuan Li, Zhengyi Qu · 2024
Read PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke by Lin Zhou, Hongyu Zhang, Shuyi Wang, Hong Zhao, Yongnan Li, Juqian Han, Hongxu Zhang, Xiaoyuan Li, Zhengyi Qu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10808616.txt.
Description
Lin Zhou and eight co-authors review PCSK9 inhibitors as a new direction for treating ischemic stroke, in a review published in 2023. Ischemic stroke is a leading cause of disability and death worldwide. Care today leans heavily on control of blood lipids to prevent and treat such strokes.
PCSK9 is a protein that raises cholesterol by cutting the number of receptors that clear it from blood. Drugs that block it lower lipids strongly and show promise in cutting stroke events. The review covers the link between PCSK9 and stroke risk, how the drugs work, and trial evidence for their benefit. It gives clinicians a single source on a fast moving treatment area.
Catalog record
| CREATOR | Lin Zhou, Hongyu Zhang, Shuyi Wang, Hong Zhao, Yongnan Li, Juqian Han, Hongxu Zhang, Xiaoyuan Li, Zhengyi Qu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |